Inventiva and Echosens collaborate to bring awareness to NASH and encourage screening for at-risk patients
June 8, 2023Medical Education Echosens, Hepatology, Inventiva, liver disease, nash, non-alcoholic steatohepatitis
French clinical stage biopharmaceutical company Inventiva has announced a collaboration with US-based high-technology company Echosens to bring attention to, and …
Inizio launches strategic engagement offering to transform customer experiences
June 7, 2023Business Services Inizio, Inizio Engage, commercialisation
6 June 2023 – London, UK — Inizio, a global commercialisation partner dedicated to the health and life sciences industry, …
Fosun Pharma and IFC partner to improve access to medicines in Africa
June 7, 2023Manufacturing and Production Africa, Fosun Pharma, IFC, Infections and infestations, manufacturing
Shanghai Fosun Pharmaceutical Group has announced a partnership with the International Finance Corporation (IFC) with the aim of helping the …
GSK’s RSV vaccine approved in EU for older adults
June 7, 2023Medical Communications EU, GSK, Infections and infestations, RSV, Vaccine
GSK has announced that the European Commission (EC) has authorised Arexvy, the company’s respiratory syncytial virus (RSV) vaccine for active …
Axol Bioscience and StrataStem collaborate to deliver ‘clinical trial in a dish’ for Alzheimer’s disease
June 7, 2023Research and Development Alzheimer's, Axol Bioscience, Neurology, StrataStem
Pluripotent stem cell technology provider Axol Bioscience has signed an exclusive agreement with UK-based StrataStem to access and commercialise its …
UK plans £40m drug trial for Novo Nordisk’s Wegovy to aid NHS in treating obesity
June 7, 2023Research and Development NHS, Novo Nordisk, Obesity, Wegovy, clinical trial, obesity
The UK Government has announced plans to launch a pilot programme which will provide GPs with Novo Nordisk’s Wegovy (semaglutide), …
GRAIL and University of Oxford showcase first prospective study results for multi-cancer early detection test
June 6, 2023Research and Development Cancer, GRAIL, Oncology, University of Oxford, cancer testing
US-based healthcare company GRAIL and the University of Oxford, UK, have announced encouraging first prospective study results at the American …
ISA Pharmaceuticals highlights positive clinical data at ASCO
June 6, 2023Research and Development ASCO, Cancer, HPV, ISA Pharmaceuticals, Oncology
Clinical stage biotechnology company ISA Pharmaceuticals has announced positive phase 1 data at the American Society of Clinical Oncology (ASCO) …
Bellerophon shares top-line data from phase 3 trial of INOpulse for fILD
June 6, 2023Medical Communications Bellerophon Therapeutics, Cardiology, clinical trials, fibrotic interstitial lung disease
Bellerophon Therapeutics has announced top-line results from its phase 3 REBUILD trial evaluating the safety and efficacy of INOpulse for …
GSK receives FDA file acceptance for Jemperli plus chemotherapy for treating endometrial cancer
June 6, 2023Research and Development GSK, Jemperli, Oncology, endometrial cancer, oncology
GSK has announced that the US Food and Drug Administration (FDA) has accepted the supplemental Biologics License Application (sBLA) for …
AstraZeneca’s phase 4 trial stopped early after reaching pre-specified criteria
June 5, 2023Research and Development ANNEXA-I, Andexxa, AstraZeneca, Neurology, clinical trial
AstraZeneca has announced that its post-marketing phase 4 ANNEXA-I trial has been stopped early after reaching its pre-specified stopping criteria. …
Quanticate announces strategic partnership with KPS Life
June 5, 2023Medical Communications KPS Life, Pharmacy, Quanticate, fsp
Global biometric clinical research group Quanticate has announced a strategic partnership with US-based provider of functional service provision (FSP) solutions …
Allogene Therapeutics shares updated ALLO-501/501A phase 1 data in large B-cell lymphoma at ASCO annual meeting
June 5, 2023Research and Development Allogene, LBCL, Oncology, lymphoma, oncology
Allogene Therapeutics has shared updated data from the phase 1 ALPHA/ALPHA2 trials of ALLO-501/501A in patients with relapsed/refractory (r/r) large …
Report finds NHS may miss out on new drugs due to rising costs
June 5, 2023Sales and Marketing LSE, LSHTM, NHS, Pharmacy, University of York, drug prices
Figures from a team at the University of York, the London School of Economics and Political Science (LSE) and the …
NICE approves first treatment for obstructive HCM for NHS use
June 2, 2023Medical Communications Bristol-Myers Squibb, Cardiology, NHS, NICE, obstructive HCM
The National Institute for Health and Care Excellence (NICE) has announced that it has approved mavacamten (Camzyos) for the treatment …
NICE recommends Pfizer’s rimegepant for preventing episodic migraine attacks
June 2, 2023Medical Communications NHS, NICE, Neurology, Pfizer, migraine
The National Institute for Health and Care Excellence (NICE) has announced that it has recommended an oral treatment for the …
BioInvent receives Investigational New Drug approval for monoclonal antibody BI-1910
June 2, 2023Research and Development BioInvent, NSCLC, Oncology, monoclonal antibody
Swedish clinical stage biotech company BioInvent has announced that it has received Investigational New Drug (IND) approval for its monoclonal …
European Parliament shares goal to tackle antimicrobial resistance
June 2, 2023Medical Communications EU, European Parliament, Microbiology, antimicrobial resistance
The European Parliament has shared its recommendations for a “coordinated EU response to health threats posed by antimicrobial resistance,” according …
FDA approves ANDA of 20mg generic Nitisinone capsules
June 1, 2023Medical Communications Analog Pharma, Dipharma, FDA, Nitisinone, Rare Diseases
Analog Pharma and Dipharma have announced that the US Food and Drug Administration (FDA) has approved their 20mg nitisinone capsules, …
FDA approves Pfizer’s RSV vaccine for older adults
June 1, 2023Research and Development FDA, Infections and infestations, Pfizer, RSV, Vaccine
Global pharmaceutical company Pfizer has announced that the US Food and Drug Administration (FDA) has approved its respiratory syncytial virus …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
